stockportfolio.pro
Stocks / ADCT vs STTK
ADCT vs STTK
ADC Therapeutics SA and Shattuck Labs, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| ADC Therapeutics SA (ADCT) | Shattuck Labs, Inc. (STTK) | |
|---|---|---|
| Market cap | $0.1B | $0.3B |
| Revenue (latest FY) | $81.36M | $1.00M |
| Net income (latest FY) | $-142.62M | $-48.81M |
| Revenue growth (5y CAGR) | -27.1% | -36.8% |
| Net margin | -175.3% | -4880.9% |
| Return on equity | 76.7% | -59.2% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ADCT — free Open STTK — freeFrequently asked questions
Which is bigger, ADCT or STTK?
Shattuck Labs, Inc. is larger by market capitalization — $0.3B versus $0.1B.
Which grows faster, ADCT or STTK?
Over the last five fiscal years, ADC Therapeutics SA grew revenue faster — -27.1%/yr versus -36.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.